Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer

Table 1

NeuGc-GM3 immunopositivity in neuroectodermal pediatric tumors.

Tumor variant	NeuGc-GM3
	Positive cases^a (%)	Positive tumor cells^b (%)	Predominant intensity^c
Neuroblastoma, NMYC-amplified	9/11 (81)	66 ± 11.6	2+/3+
Neuroblastoma, NMYC-nonamplified	9/11 (81)	69 ± 10.6	2+/3+
Ewing sarcoma family of tumors (ESFT)	5/5 (100)	71 ± 6.0	2+
Total	23/27 (85)	68 ± 6.3	2+

^aPositive/total cases.
^bValues are means ± SEM.
^cIntensity of the positive staining was graded as 1+ = mild; 2+ = moderate; 3+ = intense.